Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.
Advertisement

Related Content

Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

Topics

Advertisement
UsernamePublicRestriction

Register

PS072473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel